Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 837 matching drugs for STK11 — including drugs targeting any of its 141 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
lazertinib and amivantamab EGFR SSL via EGFR 1
osimertinib EGFR SSL via EGFR yes 1
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab ABL1 SSL via ABL1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab CTLA4 SSL via CTLA4 4
nivolumab, ipilimumab CTLA4 SSL via CTLA4 4
paclitaxel + carboplatin, carboplatin + etoposide, gemcitabine + carboplatin, nab-paclitaxel (paclitaxel-albumin) + carboplatin, oxaliplatin + 5-fluorouracil (5fu) + leucovorin (calcium folinate/folinic acid), durvalumab, tremelimumab, nab-paclitaxel (paclitaxel-albumin) + gemcitabine, cisplatin + 5-fluorouracil (5fu) CTLA4 SSL via CTLA4 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) ABL1 SSL via ABL1 4
7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis PDPK1 SSL via PDPK1 3
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine TYMS SSL via TYMS 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ABL1 SSL via ABL1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib BTK SSL via BTK 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib MAP2K1 SSL via MAP2K1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib MAPK1 SSL via MAPK1 3
biospecimen collection, computed tomography, echocardiography, ipilimumab, magnetic resonance imaging, nivolumab CTLA4 SSL via CTLA4 3
capecitabine, cisplatin TYMS SSL via TYMS 3
gemcitabine TYMS SSL via TYMS 3
nivolumab or pembrolizumab (dependent upon approved indication), metformin, rosiglitazone RXRB SSL via RXRB 3
srf617, gemcitabine, albumin-bound paclitaxel, pembrolizumab TYMS SSL via TYMS 3
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin TYMS SSL via TYMS 2
ab598, zimberelimab, fluorouracil, leucovorin, oxaliplatin TYMS SSL via TYMS 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ABL1 SSL via ABL1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel MAP2K1 SSL via MAP2K1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel TYMS SSL via TYMS 2
alvocidib, paclitaxel CDK9 SSL via CDK9 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan TYMS SSL via TYMS 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine TYMS SSL via TYMS 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 TYMS SSL via TYMS 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment ABL1 SSL via ABL1 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment BTK SSL via BTK 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment TYMS SSL via TYMS 2
bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis TYMS SSL via TYMS 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib MAP2K1 SSL via MAP2K1 2
biospecimen collection, computed tomography, devimistat, fluorouracil, gemcitabine hydrochloride, hydroxychloroquine, magnetic resonance imaging TYMS SSL via TYMS 2
biospecimen collection, computed tomography, pemetrexed TYMS SSL via TYMS 2
bms-986207, nivolumab, ipilimumab CTLA4 SSL via CTLA4 2
capecitabine TYMS SSL via TYMS yes 2
capecitabine, carboplatin, epirubicin hydrochloride TYMS SSL via TYMS 2
capecitabine, docetaxel TYMS SSL via TYMS 2
capecitabine, irinotecan hydrochloride TYMS SSL via TYMS 2
capecitabine, oxaliplatin TYMS SSL via TYMS 2
capecitabine, oxaliplatin, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, quality-of-life assessment, radiation therapy TYMS SSL via TYMS 2
capecitabine, temozolomide TYMS SSL via TYMS 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy PDPK1 SSL via PDPK1 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy TYMS SSL via TYMS 2
cetuximab, cisplatin, fluorouracil, conventional surgery TYMS SSL via TYMS 2
cft1946, trametinib, cetuximab MAP2K1 SSL via MAP2K1 2
chemotherapy, cisplatin, fluorouracil, low-let electron therapy, low-let photon therapy TYMS SSL via TYMS 2
cisplatin, fluorouracil, conventional surgery, neoadjuvant therapy, radiation therapy TYMS SSL via TYMS 2
cisplatin, fluorouracil, iressa, conventional surgery, radiation therapy TYMS SSL via TYMS 2
cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy TYMS SSL via TYMS 2
cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy TYMS SSL via TYMS 2
cisplatin, fluorouracil, surgical procedure, radiation therapy TYMS SSL via TYMS 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab TYMS SSL via TYMS 2
cobimetinib, mehd7945a MAP2K1 SSL via MAP2K1 2
cpt- 11, cisplatin, celecoxib, radiation, surgery PDPK1 SSL via PDPK1 2
durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel CTLA4 SSL via CTLA4 2
durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel TYMS SSL via TYMS 2
durvalumab, tremelimumab, sbrt CTLA4 SSL via CTLA4 2
erlotinib hydrochloride, oxaliplatin, fluorouracil, radiation therapy, conventional surgery, immunohistochemistry staining method, positron emission tomography, computed tomography, laboratory biomarker analysis, gene expression analysis, fludeoxyglucose f 18 TYMS SSL via TYMS 2
filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy TYMS SSL via TYMS 2
filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy TYMS SSL via TYMS 2
fluorouracil, gemcitabine hydrochloride, leucovorin calcium TYMS SSL via TYMS 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, pharmacogenomic studies, pharmacological study TYMS SSL via TYMS 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study HDAC3 SSL via HDAC3 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study TYMS SSL via TYMS 2
fluorouracil, oxaliplatin, conventional surgery, radiation therapy TYMS SSL via TYMS 2
ibrutinib BTK SSL via BTK yes 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide TYMS SSL via TYMS 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib TYMS SSL via TYMS 2
ipilimumab CTLA4 SSL via CTLA4 2
irinotecan, capecitabine TYMS SSL via TYMS 2
jab-3312, binimetinib, pembrolizumab, sotorasib, osimertinib MAP2K1 SSL via MAP2K1 2
laboratory biomarker analysis, oxaliplatin, pralatrexate TYMS SSL via TYMS 2
ly3022855, durvalumab, tremelimumab CTLA4 SSL via CTLA4 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab TYMS SSL via TYMS 2
m6620, cisplatin, capecitabine, radiotherapy TYMS SSL via TYMS 2
mirdametinib, bgb-3245 MAP2K1 SSL via MAP2K1 2
mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed TYMS SSL via TYMS 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a TYMS SSL via TYMS 2
nab-paclitaxel, gemcitabine TYMS SSL via TYMS 2
nivolumab, ipilimumab, cobimetinib CTLA4 SSL via CTLA4 2
nivolumab, ipilimumab, cobimetinib MAP2K1 SSL via MAP2K1 2
ociperlimab, tislelizumab, pemetrexed, paclitaxel, nab paclitaxel, carboplatin, cisplatin, etoposide, 5fluorouracil, oxaliplatin, capecitabine TYMS SSL via TYMS 2
oleclumab, durvalumab, gemcitabine, nab-paclitaxel, oxaliplatin, folinic acid, 5-fu TYMS SSL via TYMS 2
oxaliplatin, irinotecan hydrochloride, leucovorin calcium, fluorouracil, laboratory biomarker analysis TYMS SSL via TYMS 2
pembrolizumab, guadecitabine, mocetinostat HDAC3 SSL via HDAC3 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu TYMS SSL via TYMS 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin TYMS SSL via TYMS 2
pemetrexed, bevacizumab TYMS SSL via TYMS 2
pharmacological study, romidepsin ABCC1 SSL via ABCC1 2
pharmacological study, romidepsin HDAC4 SSL via HDAC4 2
pralatrexate, docetaxel, fludeoxyglucose f 18, positron emission tomography TYMS SSL via TYMS 2
regorafenib ABL1 SSL via ABL1 yes 2
regorafenib, laboratory biomarker analysis ABL1 SSL via ABL1 2
sar444881, pembrolizumab, cetuximab, carboplatin, pemetrexed TYMS SSL via TYMS 2
selumetinib, medi4736, tremelimumab CTLA4 SSL via CTLA4 2
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.